Roivant Sciences Ltd. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect the Board of Directors' three nominees for Class I Director to serve for a three-year term: Matthew Gline

Roivant Sciences Ltd.’s own tally for this item (“Elect Director: Matthew Gline”): 430,013,727 for, 154,432,135 withheld, per its Form 8-K filed September 11, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) Shareholders re-elected the individuals named below to serve as Class I directors of the Company, to hold office until the date of the annual general meeting of shareholders following the fiscal year ending March 31, 2028, and until their successors are duly elected and qualified, or until such…”
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 93,276,845 for, 34,310,335 withheld, 1,462,797 abstained.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Description as filed by funds: To elect the Board of Directors' three nominees for Class I Director to serve for a three-year term: Keith Manchester

Roivant Sciences Ltd.’s own tally for this item (“Elect Director: Keith Manchester”): 412,869,513 for, 171,576,349 withheld, per its Form 8-K filed September 11, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) Shareholders re-elected the individuals named below to serve as Class I directors of the Company, to hold office until the date of the annual general meeting of shareholders following the fiscal year ending March 31, 2028, and until their successors are duly elected and qualified, or until such…”
Support: 71% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 87,230,772 for, 40,356,407 withheld, 1,462,798 abstained.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Description as filed by funds: To elect the Board of Directors' three nominees for Class I Director to serve for a three-year term: Melissa Epperly

Roivant Sciences Ltd.’s own tally for this item (“Elect Director: Melissa Epperly”): 429,542,705 for, 154,903,157 withheld, per its Form 8-K filed September 11, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “(1) Shareholders re-elected the individuals named below to serve as Class I directors of the Company, to hold office until the date of the annual general meeting of shareholders following the fiscal year ending March 31, 2028, and until their successors are duly elected and qualified, or until such…”
Support: 73% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 92,845,203 for, 34,741,977 withheld, 1,462,797 abstained.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Description as filed by funds: To cast a non-binding, advisory vote to approve the compensation of our named executive officers.

Roivant Sciences Ltd.’s own tally for this item (“3. On a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, including the compensation tables and related narrative disclosures”): 316,651,402 for, 203,244,184 against — passed, per its Form 8-K filed September 11, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(3) Shareholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, including the compensation tables and related narrative disclosures.”
Support: 61% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 70 managers: 19,804,659 for, 109,161,237 against, 84,082 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 245 managers: 114,302,908 for, 127,211,137 against, 63,894,716 abstained, 4,971 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Roivant's independent registered public accounting firm for Roivant's fiscal year ending March 31, 2026, to appoint Ernst & Young LLP as auditor for statutory purposes under the Bermuda Companies Act 1981, as amended, for Roivant's fiscal year ending March 31, 2026, and to authorize the Board of Directors, through the Audit Committee, to set the remuneration for Ernst & Young LLP as Roivant's auditor for Roivant's fiscal year ending March 31, 2026.

Roivant Sciences Ltd.’s own tally for this item (“2. The appointment of Ernst & Young LLP ("EY") to serve as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2026, and to appoint EY as the Company's auditor for statutory p”): 628,068,956 for, 479,264 against — passed, per its Form 8-K filed September 11, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(2) Shareholders ratified the appointment of Ernst & Young LLP ("EY") to serve as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2026, and to appoint EY as the Company's auditor for statutory purposes under the Bermuda Companies Act 1981, as amended…”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Voting standard, as the filing states it: a majority of the votes cast (“majority of the votes cast”).

Also reported under other wordings, matched to the same row of Roivant Sciences Ltd.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Approve Ernst & Young LLP as Auditors and Authorize Board to Fix Their Remuneration” (4 managers, 510,219 for).

The 68 asset managers below reported 128,455,676 for, 174,310 abstained.

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.